heparin sodium (VR496) / Vectura  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
heparin sodium (VR496) / Vectura
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

Active, not recruiting
2
60
US
VRX496-Modified Autologous T cells
VIRxSYS Corporation
HIV Infection
11/08
06/23
Rollover, NCT00622232: A Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

Active, not recruiting
2
40
US
VRX496-transduced autologous CD4 T cells
VIRxSYS Corporation
HIV Infections
01/09
06/23
NCT00295477: Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV

Completed
1/2
25
US
VRX496
University of Pennsylvania, National Institute of Allergy and Infectious Diseases (NIAID)
HIV
04/10
12/13
2007-006276-11: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF)

Completed
1/2
26
Europe
Heparin 25mg inhalation powder, hard capsule, VR496,
Vectura Limited, VECTURA LIMITED
Cystic Fibrosis
 
10/10

Download Options